Pulmonx(LUNG) - 2025 Q4 - Annual Report

Financial Performance - For the years ended December 31, 2025 and December 31, 2024, the company incurred net losses of $54.0 million and $56.4 million, respectively, with an accumulated deficit of $521.6 million as of December 31, 2025[176]. - As of December 31, 2025, the company had $69.8 million in cash and cash equivalents and an accumulated deficit of $521.6 million[262]. - The company expects to continue incurring net losses for the next several years and will require substantial additional capital to finance planned operations[261]. - The company may need to raise additional capital through public or private equity offerings or debt financings, which could dilute existing stockholders' ownership[264]. Product and Market Dependence - The company relies heavily on the Zephyr Valve, which is currently approved only for treating severe emphysema, and has no other therapeutic products approved for sale in the United States[179]. - Sales of Zephyr Valves and delivery catheters accounted for most of the company's revenue for the years ended December 31, 2025 and December 31, 2024[180]. - The company derives substantially all revenue from sales to hospitals and distributors, primarily through a direct sales force engaging with pulmonologists[197]. - International sales accounted for approximately 37.0% and 32.6% of revenue for the years ended December 31, 2025, and December 31, 2024, respectively[273]. Regulatory and Compliance Challenges - The company must navigate lengthy and complex purchasing contracts with hospitals to sell the Zephyr Valve, which can delay sales and impact operating results[187]. - Compliance with extensive government regulations is critical; failure to obtain necessary approvals could negatively affect business operations[309]. - The company is under investigation by the U.S. Department of Justice regarding its relationships with healthcare providers, which could lead to increased costs and operational distractions[330]. - The company is required to report any incidents involving its products that may have caused serious injury or death, which could lead to recalls and regulatory scrutiny[324]. Clinical and Safety Concerns - In clinical trials, pneumothoraces occurred in 18-34% of patients treated with the Zephyr Valve, with 17% of these events requiring no intervention[192]. - The long-term effects of the Zephyr Valve treatment are not yet fully understood, with limited long-term data available[208]. - The success of the Zephyr Valve is contingent on adequate physician training, as improper implantation can lead to negative patient outcomes and affect market adoption[188]. - A recall of products due to safety issues could adversely affect the company's reputation and financial performance[323]. Market and Competitive Landscape - The company faces significant competition from established products and companies with greater resources, which may hinder market penetration[254]. - The total addressable market for current and future products may be smaller than estimated, particularly if smoking rates decline, which could reduce the number of patients suffering from COPD and emphysema[240]. - The overall rate of smoking among U.S. adults has declined from 42.4% in 1965 to 11.6% in 2022, which may impact the market for the company's products[240]. Operational Risks - The company faces potential challenges in maintaining physician relationships and compliance with regulatory requirements, which could impact business operations[209]. - The company relies on a limited number of single-source suppliers for critical components, making it vulnerable to supply shortages and price fluctuations[212]. - The company has limited experience in manufacturing products in significant commercial quantities, which may adversely affect its ability to meet customer demand[216]. - The company relies on third-party shipping carriers for timely delivery of its products, and any disruptions could negatively impact operations and reputation[268]. Data Privacy and Cybersecurity - The company launched the LungTraX Platform in 2024, which involves processing patient PHI, posing potential financial and reputational risks[224]. - The company is investing in protections and monitoring practices related to data and IT to reduce risks associated with security incidents[224]. - The company faces challenges in transferring personal data from Europe due to stringent localization laws and potential legal challenges to existing transfer mechanisms[374]. - The GDPR imposes substantial fines for breaches, up to €20 million or 4% of global turnover, whichever is greater, along with potential bans on data processing[373]. Future Growth and Development - The company plans to expand its sales and marketing infrastructure to increase the number of customers and emphysema centers of excellence[207]. - The company is conducting the CONVERT II pivotal trial for the AeriSeal System, aimed at treating severe emphysema patients not qualified for Zephyr Valve treatment[263]. - The company's long-term growth relies on enhancing the Zephyr Valve, Chartis System, and LungTraX Platform, as well as developing new products[293]. - Failure to expand indications and develop new products may impair revenue growth, adversely affecting the company's financial condition[294].